S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

$15.28
+0.37 (+2.48%)
(As of 03/1/2024 ET)
Today's Range
$14.85
$16.18
50-Day Range
$10.83
$16.49
52-Week Range
$9.56
$31.46
Volume
1.32 million shs
Average Volume
865,798 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.57

Zentalis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
152.4% Upside
$38.57 Price Target
Short Interest
Bearish
20.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Zentalis Pharmaceuticals in the last 14 days
Based on 38 Articles This Week
Insider Trading
Selling Shares
$42,854 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.68) to ($3.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

781st out of 952 stocks

Pharmaceutical Preparations Industry

355th out of 433 stocks


ZNTL stock logo

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

ZNTL Stock Price History

ZNTL Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Raised to $15.00
Zentalis Pharmaceuticals, Inc.
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
3/02/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZNTL
Fax
N/A
Employees
156
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.57
High Stock Price Target
$70.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+152.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-236,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.16 per share

Miscellaneous

Free Float
66,631,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
1.72
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Kimberly Lynn Blackwell M.D. (Age 55)
    CEO & Director
    Comp: $1.12M
  • Mr. Cameron S. Gallagher M.B.A. (Age 54)
    Co-Founder, President & Director
    Comp: $767.69k
  • Ms. Melissa B. Epperly M.B.A.Ms. Melissa B. Epperly M.B.A. (Age 46)
    CFO & Treasurer
    Comp: $721.64k
  • Ms. Andrea Paul J.D. (Age 42)
    Chief Legal Officer & Corporate Secretary
    Comp: $668.2k
  • Dr. Mark Lackner Ph.D. (Age 56)
    Chief Scientific Officer
  • Dr. Diana F. Hausman M.D. (Age 61)
    Chief Medical Officer & Director
  • Ms. Kimberly Freeman
    Chief Strategy Officer
  • Dr. Kyle Rasbach Ph.D. (Age 44)
    Pharm.D., Chief Business Officer
  • Dr. Adrian Jubb M.D.
    Ph.D., Executive Vice President of Clinical Development














ZNTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zentalis Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ZNTL shares.
View ZNTL analyst ratings
or view top-rated stocks.

What is Zentalis Pharmaceuticals' stock price target for 2024?

7 analysts have issued 12-month target prices for Zentalis Pharmaceuticals' shares. Their ZNTL share price targets range from $15.00 to $70.00. On average, they predict the company's stock price to reach $38.57 in the next year. This suggests a possible upside of 152.4% from the stock's current price.
View analysts price targets for ZNTL
or view top-rated stocks among Wall Street analysts.

How have ZNTL shares performed in 2024?

Zentalis Pharmaceuticals' stock was trading at $15.15 at the start of the year. Since then, ZNTL shares have increased by 0.9% and is now trading at $15.28.
View the best growth stocks for 2024 here
.

When is Zentalis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ZNTL earnings forecast
.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) posted its quarterly earnings results on Monday, November, 6th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.13. During the same period in the prior year, the company posted ($0.96) earnings per share.

What ETFs hold Zentalis Pharmaceuticals' stock?

ETFs with the largest weight of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

(ZNTL) raised $131 million in an IPO on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (16.29%), Vanguard Group Inc. (7.56%), Price T Rowe Associates Inc. MD (4.10%), Price T Rowe Associates Inc. MD (4.09%), Capital International Investors (3.98%) and Federated Hermes Inc. (3.05%). Insiders that own company stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, Carrie Brownstein, David Michael Johnson, Dimitris Voliotis, Jan Skvarka, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell, Matrix Capital Management Comp and Melissa B Epperly.
View institutional ownership trends
.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZNTL) was last updated on 3/2/2024 by MarketBeat.com Staff